
|Articles|September 22, 2015
Shaji Kumar on Later Lines of Treatment for Myeloma
Author(s)Shaji Kumar
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Advertisement
Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, provides an overview of later lines of therapy for patients with multiple myeloma.
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
5 Years of Prostate Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
5 Years of Lung Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
3
At 21 I Was Given 18 Months. This Year I Turned 40.
4
Top 3 Takeaways From WCLC 2026 That Patients Should Know
5




